Search clinical trials for: capecitabine erlotinib

Total 3179 results

Grupo Gallego de Investigaciones Oncologicas

Completed

Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients (XELTA)

Metastatic Adenocarcinoma of the Pancreas

Spain
Peter Kozuch
Hoffmann-La Roche; Genentech, Inc.

Terminated

Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Sun Yat-sen University

Completed

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

Non-small Cell Lung Cancer

China
Milton S. Hershey Medical Center
Genentech, Inc.

Completed

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Spanish Cooperative Group for the Treatment of...
Hoffmann-La Roche

Completed

Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer (GECA)

Metastatic Pancreatic Cancer

Spain
Merck Sharp & Dohme LLC

Completed

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Breast Neoplasms | Carcinoma, Non-Small-Cell Lung
Loma Linda University

Terminated

Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Henan Cancer Hospital

Not yet recruiting

TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction
Centre Antoine Lacassagne

Completed

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

France
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (ALTER-HN005)

Nasopharyngeal Neoplasms
Hoffmann-La Roche

Completed

ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer

Pancreatic Cancer

Austria
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
Albert Einstein College of Medicine
Shanghai Proton and Heavy Ion Center

Completed

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Cancer | Pancreatic Cancer

United States, China
GERCOR - Multidisciplinary Oncology Cooperative...

Completed

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Cancer

France
Centro Nacional de Investigaciones Oncologicas...
Apices Soluciones S.L.; Hospital Universitario de Fuenlabrada; Grupo Hospital...

Completed

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Advanced Pancreatic Carcinoma

Spain
Lund University Hospital
Hoffmann-La Roche

Completed

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. (ACT2)

Colorectal Cancer

Sweden, Denmark
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

China
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

Spain
The First Affiliated Hospital with Nanjing Medical...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma (EXPLORING)

Digestive System Diseases | Gastrointestinal Diseases | Carcinoma | Gastrointestinal Neoplasms | Stomach Cancer | Gastric Cancer | Gastroesophageal-junction Cancer

China
PD Dr. med. Volker Heinemann
Roche Pharma AG

Unknown

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Pancreatic Cancer
Zhejiang University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (ALTER-C-002)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Colonic Diseases | Intestinal Diseases | Colorectal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | RAS and BRAF Wild-type

China
Duke University
Genentech, Inc.

Completed

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Glioblastoma | Gliosarcoma

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma (TAXE-GC)

Gastric Cancer

China
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Hoffmann-La... and other collaborators

Completed

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

Neoplasm Metastasis | Colorectal Cancer

United States
Dutch Colorectal Cancer Group
Sanofi; Roche Pharma AG; Koningin Wilhelmina Fonds; Immunicon

Completed

Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Colorectal Cancer

Netherlands
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Rectal Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Tarceva and Capecitabine for Pancreatic Cancer

Neoplasm Metastasis | Pancreatic Cancer

United States
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Federation Francophone de Cancerologie Digestive

Recruiting

Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over (ADAGE)

Colonic Adenocarcinoma

France
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
M.D. Anderson Cancer Center

Completed

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Advanced Cancers

United States
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Malignant Peritoneal Mesothelioma

United States
Grupo de Investigación Clínica en Oncología Radioterapia

Completed

Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Spain
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Merck Sharp & Dohme LLC

Completed

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Carcinoma, Non-small Cell Lung
Duke University
Bristol-Myers Squibb; Genentech, Inc.

Completed

Ph I Dasatinib + Erlotinib in Recurrent MG

Glioblastoma | Gliosarcoma

United States
Tragara Pharmaceuticals, Inc.

Completed

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (TP2001-201)

Recurrent Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
University of California, Davis
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Non Small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Carcinoma, Non-small-cell Lung
PharmaMar

Completed

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

Spain, United States
New Mexico Cancer Care Alliance

Completed

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Advanced Solid Tumor Malignancies

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Breast Cancer

United States

Search clinical trials for: capecitabine erlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations